Cambridge, UK, 18 Feb 2022:  The o2h human health KI EIS Fund is pleased to announce a follow-on investment into Oxford Drug Design (ODD), an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. 

ODD are discovering new drugs with differentiated modes of action against challenging diseases with high unmet medical need. Based on a core competence platform in tRNA synthetase enzymes and distinctive AI/ML methods, their pipeline expansion is focused on oncology.

Prior to this, o2h Ventures invested in ODD’s major funding round in July 2019 where ODD won major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totaling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform.

Sunil Shah, CEO at o2h Ventures said, “ODD has made great progress with its lead programme which stemmed from their proprietary machine platform which they pioneered and developed.  This puts them in an exclusive club, the next phase is to now monetize this platform on other new targets.”

About ODD

Founded in 2001, Oxford Drug Design is an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods.

They’re developing innovative medications with distinct mechanisms of action for difficult diseases with high unmet medical needs. Their pipeline expansion is focused on cancer and is based on a core competence platform in tRNA synthetase enzymes and unique AI/ML methodologies. Their differentiated drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action against urgent pathogens.

For more information, please visit – https://oxforddrugdesign.com/ 

About o2h ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com

Media Contact:

Ayushi Vijayvargiya

Marketing Executive

ayushi.vijayvargiya@o2h.com

o2h-ventures